SELL or significantly larger trim (75-100% recommended)

• 50 percent trim is a half-measure that leaves firm dangerously exposed to quantifiable risks
• BMY market cap of 133 billion with 50 percent allocation to single pharma name facing patent cliff in 12 to 18 months is massive concentration risk
• Dividend yield of 3.73 percent (approximately 2.4 billion annually on full position, 1.2 billion on retained half) does not compensate for Eliquis erosion tail risk
• Stop at 68.50 is above entry at 66.00, functioning as re-evaluation trigger rather than true risk management stop
• No defined exit rule exists if price breaks below 60.15 (50-day SMA), which would invalidate the uptrend thesis
• Federal appeals court reinstated 6.7 billion dollar claim alleging deliberate delay of FDA approvals to dodge contingent value rights
• Even settlement of 2 to 3 billion equals roughly 4 to 6 percent of market cap
• Fundamentals show negative tangible book value of negative 22.6 billion dollars, meaning equity base is goodwill and intangibles from acquisitions (Celgene, Karuna, Mirati, RayzeBio)
• 13.9 billion in impairment charges already recorded in 2023; risk of another write-down is structural, not theoretical
• Management has suspended buybacks entirely to focus on deleveraging, signaling balance sheet priority over capital appreciation
• Entry at 66.00 with expectation of relief rally has execution risk given failed breakouts at 67.08 and 68.64 with bearish MACD cross
• Proposed Option A: increase trim to 75 or 100 percent given unfavorable risk-reward
• Proposed Option B: add hard rule to exit remainder immediately if BMY closes below 60.15 on any daily session
• Re-entry criteria should require confirmed close above 68.50 with volume greater than 13 million shares AND no negative lawsuit news flow

→ vs aggressive: The 50 percent trim framed as tactical asymmetry is actually a half-measure; the asymmetry runs the other way when pricing in structural Eliquis patent erosion

→ vs aggressive: Holding 50 percent as a 'free option' ignores that a patent cliff is not a one-time event that can be options-strategized around

→ vs aggressive: The lawsuit dismissed as 'elephant in the room' still leaves half the position exposed to a 6.7 billion dollar claim with punitive damage potential

→ vs aggressive: Waiting for relief rally to 66 to trim creates execution risk when MACD has already crossed bearish and price has failed at 67.08 and 68.64

→ vs aggressive: Reloading at 58 to 62 after a broken trend is catching a falling knife, not value buying

TRIM 50-60% of position across 64-67 price band over 5-10 day execution window; retain 50% with hard exit rules

• 50 percent trim is reasonable starting point but should not exceed 60 percent without confirmed breakdown below 60.15
• Trim execution should use 64-67 price band rather than fixating on 66; allow for grinding lower to 63-64 before trimming
• Retained 50 percent is not a 'free option' as aggressive analyst claims—it carries real exposure to 6.7 billion lawsuit, patent cliff, and negative tangible book value
• Lawsuit is being underweighted: federal appeals court reinstated the claim and plaintiffs allege intentional delay of FDA approvals to dodge CVRs
• Patent cliff is multi-year managed erosion, not sudden cliff event—forward P/E of 9.98x shows market already pricing in LOE
• Lawsuit is probabilistic overhang, not guaranteed loss—settlement fractions headline amount and takes years to resolve
• Balance sheet shows healthy deleveraging: net debt down 4.4 billion YoY, FCF coverage 2.5x, current ratio 1.53
• Management buyback suspension reflects responsible capital allocation post-M&A, not a bearish signal
• Structural support intact: 50 SMA, 200 SMA, and Bollinger midline all within 5 percent of price
• Retained position needs hard exit rule: daily close below 60.15 on above-average volume triggers full exit with no discretion
• Second exit trigger: adverse class certification ruling or denial of motion to dismiss in Celgene lawsuit triggers exit of half the retained position
• Re-entry requires daily close back above 50 SMA with above-average volume (downside) OR close above 68.50 with volume above 13 million shares (upside)
• Dividend at 3.73 percent yield with 2.5x FCF coverage cushions holding but does not justify holding through structural earnings reset
• Macro defensive rotation is a tailwind but does not resolve company-specific risks; neither justifies adding nor full exit

→ vs aggressive: Retained half called 'free option' is metaphor dressed as math—carries real exposure to 6.7 billion lawsuit, patent cliff, negative tangible book value

→ vs aggressive: Asymmetry framing cherry-picks favorable scenario—if BMY breaks 60.15 on volume, retained 50 percent absorbs entire drawdown

→ vs aggressive: Lawsuit underweighted by leaving half position exposed to federal appeals court reinstated claim with intentional FDA delay allegations

→ vs conservative: Patent cliff treated as sudden cliff event rather than multi-year managed erosion—forward P/E 9.98x shows market already discounted meaningful chunk

→ vs conservative: Lawsuit presented as near-certain binary event when it's probabilistic—cases settle for fractions of headline amount and take years

→ vs conservative: Management buyback suspension is responsible capital allocation post 20B+ M&A, not a bearish signal—net debt down 4.4B, FCF coverage 2.5x

→ vs conservative: Critique of 66 entry overstates urgency—selling at 65.47 not materially different from selling at 66 in risk management terms